Member Info for EmeraldCarrots

Peter Collins says there is big demand for analysing circulating tumor cells (CTCF's) as some of the information they can provide cannot be obtained by other means, including CtDna and CfDna. The "Master Services Agreement" that is expected to be signed any day I suspect will be just the first one. I expect it will be with Astrazeneca. The other top Pharma Plc's in the World will take note and there is no current reason why other massive Pharma Co's won't do the same.

1. Eli Lilly and Company (USA): Often recognized as the top player by market capitalization, largely driven by its diabetes and obesity therapies (Mounjaro/Zepbound).

2. Novo Nordisk (Denmark): A massive player in metabolic health (Ozempic/Wegovy), frequently ranking alongside Eli Lilly as one of the most valuable pharmaceutical firms.

3. Johnson & Johnson (USA): A diverse health giant with significant revenue in immunology, oncology, and neuroscience.

4. AbbVie (USA): A dominant leader in immunology (Humira/Skyrizi) and oncology.

5. Roche (Switzerland): A leader in oncology and diagnostics, often ranking high due to strong revenue in specialized medicine.

6. Merck & Co. (USA): Known as MSD outside the US and Canada, driven by its massive blockbuster cancer therapy, Keytruda.

7. AstraZeneca (UK): A major player in oncology, respiratory, and cardiovascular drugs.

8. Novartis (Switzerland): A leader in innovative medicines, particularly in gene therapy, cardiovascular, and immunology.

9. Amgen (USA): A biotechnology giant with a strong portfolio in inflammation, oncology, and bone health.

10. Gilead Sciences (USA): A leader in antiviral treatments (HIV, Hepatitis) and expanding in oncology.

.

"a pharma major we will start working with in the very near future". It's a done deal then.

Https://www.proactiveinvestors.co.uk/companies/news/1092104/cellbxhealth-targets-growth-after-6-6m-cost-cutting-overhaul-1092104.html

"a further 2 nr. RNS's **expected anytime**" ......................................

Got, rather than spending time on another machine. I am not happy with Gino at all. Genedrive have TWO World class machines and as far as I can see NO SALES drive to speak of. The man needs to get his act together and take on people to spread the word and increase SALES. Maybe he should step down to do his inventing and get someone else in to run the Company?

All IMHO.

1. "Master Services Agreement" with a top ten global pharmaceutical company. Astrazeneca?

2. Two clinical studies with one of the largest private US healthcare providers. Solaris?

=====================================

Can't wait to find out who there Companies are. What if the Master Services Agreement turns out to be Johnson and Johnson, Eli Lilly, or Pfizer !!!!!!!

1. "Master Services Agreement" with a top ten global pharmaceutical company. Astrazeneca?

2. Two clinical studies with one of the largest private US healthcare providers. Solaris?

================================

Sp likely to get 2 spikes up, possibly just a day apart! North of 1.75p very likely IMHO!!!!!!!!!!!!!!!!!!!

1. "Master Services Agreement" with a top ten global pharmaceutical company. Astrazemeca?

2. Two clinical studies with one of the largest private US healthcare providers. Solaris?

Just been checking and it could be Solaris. So Solaris, or Myriad Genetics. Hope it's Solaris as they deal with prostate cancer, the most common cancer men get in the World.

Agreement are with the same Company. I.E Astrazeneca. But that is incorrect. Looking again. Clearly the "Master Services Agreement with a top ten global pharmaceutical company" is just the services agreement. Separately the two clinical studies is with one of the largest private US healthcare providers. Likely Myriad Genetics. So probably Astrazeneca for the services agreement and Myriad for the 2 trials. Jolly good x 2!!!!

==============

The clinical studies could easily also be with Immatics Inc. So Immatics or Myriad. **JOY!!!!**.

All IMHO.

"The Company is in advanced discussions with one of the largest private US healthcare providers to use CelLBxHealth's Parsortix® platform in two clinical studies and is also in the final stages of concluding a Master Services Agreement with a top ten global pharmaceutical company for the use of the Parsortix® platform to potentially support drug discovery and developmen

Agreement are with the same Company. I.E Astrazeneca. But that is incorrect. Looking again. Clearly the "Master Services Agreement with a top ten global pharmaceutical company" is just the services agreement. Separately the two clinical studies is with one of the largest private US healthcare providers. Likely Myriad Genetics. So probably Astrazeneca for the services agreement and Myriad for the 2 trials. Jolly good x 2!!!!

All IMHO.

"The Company is in advanced discussions with one of the largest private US healthcare providers to use CelLBxHealth's Parsortix® platform in two clinical studies and is also in the final stages of concluding a Master Services Agreement with a top ten global pharmaceutical company for the use of the Parsortix® platform to potentially support drug discovery and development."

Proved they can sell a cold bottle of pure spring water to a person dying of thirst? LOL!

======================

Now they just need one baby that can hear, and maybe one that has been made deaf due to a bad reaction to antibiotics given in a neonatal ward. Then tell the person "this is what we are aiming for (the baby that can hear). LOL!

Proved they can sell a cold bottle of pure spring water to a person dying of thirst? LOL!

"The Company is in advanced discussions with one of the largest private US healthcare providers to use CelLBxHealth's Parsortix® platform in two clinical studies and is also in the final stages of concluding a Master Services Agreement with a top ten global pharmaceutical company for the use of the Parsortix® platform to potentially support drug discovery and development."

================================================

Master Services Agreement.

"What the Agreement Means for the ProviderValidated Vendor Status: Being vetted by a top-ten pharma company (e.g., Pfizer, Roche, J&J, Novartis, AstraZeneca) implies that the provider’s processes, security, and quality meet industry-leading standards.Streamlined Contracting: Instead of negotiating new contracts for every new study, subsequent projects are initiated through simplified Statement of Work (SOW) documents that reference the already-agreed-upon MSA.Long-Term Revenue Potential: These agreements are designed for ongoing, multi-year relationships, providing stability and predictable, high-volume project flow."

They run a very real risk of extreme social unrest and revolution. The people running Iran are taking a huge risk.......... that may give Trump what he wanted in the fiirst place. Foolish I think not to do a deal to get the strait unlocked. Very, very foolish indeed.

All IMHO.

Iran.

- Most of their navy has been destroyed. Fact.

- Their economy is in free-fall. Fact.

- Their GDP is about 90% of what it was due to the Strait of Hormuz being closed. fact.

- If they want more weapons (which seems to be the case) how will they pay for them? Anyone?

- If they don't open the strait soon they will lose 10 to 40% of their future oil income due to the damage to existing wells when they are shut down (they will have to be shut down when the storage tanks are full). The USA thinks they are full now in fact.

=====================

And they think the USA is going to compensate them for the war damage, AND leave them in charge of the Strait of Hormuz to charge passage!

Totally ridiculous demands in my opinion. They can't be serious about this.

When they wake up to reality maybe I'll buy some more WIZZ.

All IMHO.

"A pharma clinical study (or clinical trial) is a research investigation involving human volunteers designed to evaluate the safety, efficacy, and dosage of new drugs, biological products, or medical devices. These studies are essential, highly regulated, and structured in phases (I-IV) to determine if a new treatment is safe and more effective than existing options before it is approved for public ".

======================================#

From the RNS:-

"is in advanced discussions with one of the largest private US healthcare providers to use CelLBxHealth's Parsortix® platform in two clinical studies and is also in the final stages of concluding a Master Services Agreement with a top ten global pharmaceutical company for the use of the Parsortix® platform to potentially support drug discovery and development.".

======================================

**two clinical studies**. First ones EVER for parsortix as far as I know.

Researcher1.

"Price at close Emerald? I'll go for 1.30, and 1.45 by close Wednesday...."

========================

1.25/1.35p, so I agree the mid @ 1.3p. maybe up to 1.45/1.55 by close wednesday. So Mid 1.5p?

The massive point here is a top 10 pharma HAS concluded (for the first time!) that Parsortix IS worth using in an actual cancer drug trial.

The market has not yet taken that on board........................

All IMHO.

.

To be a sell. That is over the last 30 mins. Says it all.